Get startedLog in
    Picture of Sanofi SA logo

    SAN — Sanofi SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareBalancedLarge CapSuper Stock
    All News

    Brief: Sanofi’S Nexviazyme Met All Primary And Secondary Endpoints In Infantile-Onset Pompe Disease Phase 3 Study

    Picture of Sanofi SA logoSanofi SA
    30/06/2026 06:06
    BRIEF-Sanofi’S Nexviazyme Met All Primary And Secondary Endpoints In Infantile-Onset Pompe Disease Phase 3 Study
    June 30 (Reuters) - Sanofi SA SASY.PA:
    • SANOFI’S NEXVIAZYME MET ALL PRIMARY AND SECONDARY ENDPOINTS IN INFANTILE-ONSET POMPE DISEASE PHASE 3 STUDY
    • NEXVIAZYME WELL TOLERATED WITH NO SERIOUS TREATMENT-RELATED ADVERSE EVENTS IN BABY-COMET STUDY
    • DATA WILL SUPPORT A REGULATORY SUBMISSION FOR A LABEL EXTENSION IN US, ANTICIPATED IN SECOND HALF OF 2026
    • RESULTS WILL BE SHARED ON JULY 8, 2026, AT 19TH INTERNATIONAL CONGRESS ON NEUROMUSCULAR DISEASES IN FLORENCE, ITALY
    Source text: nGNE1gsXMy
    Further company coverage: SASY.PA

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

    Recent news on Sanofi SA

    See all news